Thanks Tada. You wrote "I think you will find that dosing of the first combination cohort did not start until mid January so with luck we will be late into the third cohort or just starting the fourth."

Plus, Zenith started the combo ZEN-3694/enzalutamide trial only after finding the maximally tolerated dose (MTD) for daily dosing in the ZEN-3694 single agent trial. My understanding is that the dose of enzalutamide is already pre-determined (I could be wrong). So if Zenith was able to start at or near the ZEN-3694 MTD found in the single agent trial, then they should arrive at the optimal dose for the combo therapy sooner than in the single agent trial. However, at last update Zenith was exploring intermittent as opposed to daily dosing for the single agent trial, so if intermittent dosing is also being explored for the combo trial then this could add complexity. And if enzalutamide has to be titrated as well, this adds additional complexity. 

Also, I see an additional error in my previous statement "The ZEN-3694/enzalutamide combo trial will have been dosing for 6 months next week and 7 months come BIO-International." It should be 5 months next week and 6 months at BIO International since the news release of combo trial initiation (not necessarily dosing) instead of the 6 month and 7 month figures. My math was off by a month.

BDAZ